Former Bulls player and executive John Paxson will be among the new members welcomed into the team’s Ring of Honor during ...

We appreciate the constructive remarks by Chung-Wei Christine Lin and colleagues regarding our systematic review and resulting recommendations.1 Our systematic review and meta-analysis were explicitly ...

A pinched nerve in your neck, also known as cervical radiculopathy, can cause pain, weakness, numbness, and limited motion, according to Cleveland Clinic. Your neck contains your cervical spine, which ...

Nearly 10% of adults will experience some form of severe neck pain in any given calendar year. Most cases of neck pain have multiple causes, such as inflamed (swollen) muscles, ligaments, joints or ...

ADDITIONAL STUDIES. WELL, IN TONIGHT’S WOMAN’S DOCTOR, IF YOU’RE FEELING STIFFNESS IN YOUR NECK THAT RADIATES DOWN YOUR ARM, NUMBNESS OR TINGLING OR WEAKNESS IN YOUR HANDS, THERE ARE TWO CONDITIONS ...

Lumbar radiculopathy, or sciatic neuritis, is a condition that usually results from a pinched nerve or a herniated disc, though other causes are possible. Typical symptoms are weakness, pain, numbness ...

This video will describe how cervical radiculopathy can cause pain, numbness and tingling down a persons arm, hands or fingers. Treatment options for this condition are also discussed. Mace leaves ...

Cervical radiculopathy is a condition caused by a pinched nerve in your neck. It happens when your cervical spinal cord or nerve roots arising from it become compressed by the cervical vertebrae. Your ...

Suzetrigine is under clinical development by Vertex Pharmaceuticals and currently in Phase II for Radiculopathy. According to GlobalData, Phase II drugs for Radiculopathy does not have sufficient ...

Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from its Phase 2 study of suzetrigine in people with painful ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...